预约演示
更新于：2025-07-15
Methylprednisolone sodium succinate
甲泼尼龙琥珀酸钠
更新于：2025-07-15
概要
基本信息
药物类型 小分子化药 |
别名 Methylprednisolone Hemisuccinate、Methylprednisolone hydrogen succinate、Methylprednisolone sodium succinate (JAN/USP) + [10] |
靶点 |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H34NaO8 |
InChIKeyWOARBZBOZOGFGA-SGJOWKDISA-N |
CAS号2375-03-3 |
关联
58
项与 甲泼尼龙琥珀酸钠 相关的临床试验NCT07054801
Intra-arterial Lidocaine and Methylprednisolone Injection Into the Middle Meningeal Artery For Treatment of Headache Associated With Subarachnoid Hemorrhage
NCT06924983
A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage.
NCT06921616
A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
100 项与 甲泼尼龙琥珀酸钠 相关的临床结果
登录后查看更多信息
100 项与 甲泼尼龙琥珀酸钠 相关的转化医学
登录后查看更多信息
100 项与 甲泼尼龙琥珀酸钠 相关的专利（医药）
登录后查看更多信息
1,824
项与 甲泼尼龙琥珀酸钠 相关的文献（医药）2025-06-01EXPERIMENTAL PARASITOLOGY
Toll-like receptors and inflammatory cytokines in the skin of Acanthamoeba spp. infected immunocompetent and immunosuppressed mice
Article
作者: Kosik-Bogacka, D ; Derda, M ; Łanocha-Arendarczyk, N ; Kot, K ; Kolasa, A ; Wojtkowiak-Giera, A ; Solarczyk, P
Acanthamoeba spp. can cause opportunistic infections, such as cutaneous acanthamoebiasis (CA). Little is known about the role of TLRs and cytokines in the host skin during Acanthamoeba spp. infections. The study aimed to examine the gene and protein expression of TLR3, TLR7, IFN-γ, and IL-23 in the skin of mice experimentally infected with a clinical strain of Acanthamoeba spp. male BALB/c mice were assigned to four groups: group I (control group I) - with normal immunity (C, n = 5); group II (control group II) - with reduced immunity induced by methylprednisolone sodium succinate (MPS; CS, n = 5); group III - amoeba-infected hosts with normal immunity (A, n = 12); and group IV- amoeba-infected hosts with reduced immunity induced by MPS (AS, n = 12). The skin sections (2 cm × 2 cm) were collected from the animals at 8, 16, and 24 days post-infection (dpi). TLR3, TLR7, IFN-γ, and IL-23 gene and protein expressions were analyzed by quantitative real-time PCR and immunohistochemical staining. In the immunocompetent hosts, we noted higher expressions of TLR3 and IL-23 at all-time points, except 8th dpi when IL-23 gene expression was downregulated compared to the control group. The mRNA expressions of TLR7 and IFN-γ were higher at 16 and 24 dpi in the skin of immunocompetent Acanthamoeba spp.-infected hosts than in the uninfected mice. In the course of acanthamoebiasis in the mice with reduced immunity, we found significant upregulation of TLR3, IL-23, and TLR7 gene expressions only at the beginning of infection compared to the control group. A similar relationship was observed for IFN-γ at 8 and 16 dpi. The pathophysiology of Acanthamoeba infection in the skin is complex. The data presented in this paper add new insight, but they are not sufficient to explain the role of the studied receptors and cytokines. The clinical picture and mechanisms of host response appear to be influenced by the route of infection, immunological status and microorganisms carried within the parasites. CA remains a multifactorial phenomenon.
2025-06-01JOURNAL OF CONTROLLED RELEASE
Comparing continuous micromixing and extrusion downsizing for PEGylated nanoliposomes remotely loaded with doxorubicin or the steroid pro-drug methylprednisolone hemisuccinate
Article
作者: Bleul, Regina ; Barenholz, Yechezkel ; Thiermann, Raphael ; Turjeman, Keren ; Paulus, Christine ; Egler-Kemmerer, Alexander-Nicholas ; Shamrakov, Dima
Since the FDA approval of the first nanodrug Doxil® in 1995, twenty subsequent liposome and lipid nanoparticle (LNP) based drugs (of which 10 are nanodrugs), were approved by the FDA. The application of such drug-products was considerably boosted by the mRNA-LNP based vaccines used to stop the COVID-19 pandemic. Research on lipid-based vesicles and nanoparticles for drug delivery dates to the 1970s and has culminated in both continuous flow and extrusion-based fabrication processes for current state-of-the-art GMP industrial production of nanoliposomes and lipid nanoparticles. In this study, we compare these two approaches for the preparation of two PEGylated nanoliposome-based drug-products, keeping all other production steps leading to the final drug-product identical. One of these products, generic Doxil®, is remotely and actively loaded with the anthracycline doxorubicin (an amphipathic weak base) driven by a transmembrane ammonium gradient, while the other is methylprednisolone hemisuccinate (an amphipathic weak acid) remotely and actively loaded via a transmembrane acetate gradient. We demonstrate that a microfluidics-based micromixer approach yields equivalent or even better drug-products, especially since the downsizing by microfluidics is not performed above the temperature range of lipid phase transition. The main difference in the physico-chemical features is that size distribution of the microfluidics prepared PEGylated nano liposomes was significantly narrower and morphological analysis by cryo-TEM confirmed higher homogeneity. An additional advantage of the microfluidic approach is that it is a continuous production. Therefore, it enables the direct production of large volumes of high-quality nano-liposomal based drug-products.
2025-05-12Cureus Journal of Medical Science
Limbic Encephalitis: An Unusual Presentation on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT)
Article
作者: Manto, Mario ; Duran Derijckere, Ivan ; Bouazza, Salima ; Moradi, Massoud ; Omatuku Wetshosele, Grégory
Limbic encephalitis is a relatively rare autoimmune neurological disorder, typically diagnosed based on clinical symptoms lasting less than three months, including seizures, memory deficits, psychiatric symptoms, bilateral mesial temporal lesions on MRI, inflammatory cerebrospinal fluid, and epileptiform activity on electroencephalogram (EEG). We report the case of a female patient who presented with an inaugural epileptic seizure, for which MRI, lumbar puncture, and cerebral positron emission tomography (PET) scan showed no pathological findings. The patient re-presented to the emergency department one month later with recurrent seizures. A subsequent PET scan revealed the emergence of a right mesial temporal lesion, and a hypermetabolic pulmonary lesion was identified, which was later diagnosed as small-cell lung carcinoma on histopathology. The patient showed favorable clinical improvement under Solu-Medrol treatment, and a follow-up imaging performed several months later showed complete resolution of the hypermetabolic cerebral lesion after chemotherapy. This case highlights an unprecedented early stage of limbic encephalitis, characterized by an initial absence of inflammation, suggesting that this might represent a nascent phase of the disease, which could be crucial for future management of similar cases.
100 项与 甲泼尼龙琥珀酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 粘膜皮肤淋巴结综合征 | 日本 | 2023-09-25 | |
| Churg-Strauss综合征 | 日本 | 2014-08-29 | |
| 肉芽肿伴多血管炎 | 日本 | 2014-08-29 | |
| 结节性多动脉炎 | 日本 | 2014-08-29 | |
| 多发性肌炎 | 日本 | 2014-08-29 | |
| 系统性红斑狼疮 | 日本 | 2014-08-29 | |
| 大动脉炎 | 日本 | 2014-08-29 | |
| 淋巴瘤 | 日本 | 2001-08-29 | |
| 肾病综合征 | 日本 | 2001-08-29 | |
| 脊髓损伤 | 日本 | 2001-08-29 | |
| 系统性血管炎 | 日本 | 2001-08-29 | |
| 艾迪生病 | 中国 | 2001-01-01 | |
| 贫血 | 中国 | 2001-01-01 | |
| 哮喘 | 中国 | 2001-01-01 | |
| 皮肌炎 | 中国 | 2001-01-01 | |
| 角膜炎 | 中国 | 2001-01-01 | |
| 白血病 | 中国 | 2001-01-01 | |
| 多发性硬化症 | 中国 | 2001-01-01 | |
| 天疱疮 | 中国 | 2001-01-01 | |
| 急性脊髓损伤 | 日本 | 1997-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶性疟 | 临床前 | 以色列 | - | |
| 视神经炎 | 临床前 | 以色列 | - | |
| 类风湿关节炎 | 临床前 | 以色列 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | Protease 3 ab | Low Complement 3 and 4 | - | High-dose Solumedrol (1g) | 壓壓遞餘網獵願鹹醖鬱(築淵網醖鹹觸願窪襯願) = Clinicians should be aware that allergic reactions to corticosteroids are possible. Worsening of symptoms may not always mean treatment failure, but may indicate an allergic reaction. High doses of corticosteroids (≥500 mg) should be given over 30-60 minutes, and patients should be observed after administration for at least the same time period. 顧構簾餘鹽壓鏇鹽淵構 (簾繭顧鬱願襯衊襯選衊 ) 更多 | - | 2025-05-16 | |
临床4期 | 89 | Low Dose Corticosteroids (Low Dose Corticosteroids) | 顧夢憲鬱憲糧膚壓膚鹽 = 鏇廠鹹鬱製膚積構範遞 簾範鬱衊鬱鹹鑰範蓋艱 (襯鹹遞鹹顧獵糧壓夢鏇, 鬱夢構鹽築繭膚糧蓋願 ~ 壓襯鏇衊構艱願廠糧網) 更多 | - | 2024-04-10 | ||
High Dose Corticosteroids (High Dose Corticosteroids) | 顧夢憲鬱憲糧膚壓膚鹽 = 顧遞築遞窪壓獵選選繭 簾範鬱衊鬱鹹鑰範蓋艱 (襯鹹遞鹹顧獵糧壓夢鏇, 壓衊構憲獵淵鬱齋積積 ~ 艱築積獵遞鹹網蓋獵鬱) 更多 | ||||||
早期临床1期 | 47 | (Group A: Glucocorticoids 1 mg/kg Dose) | 鹽窪構壓顧鏇構願鏇鑰 = 淵襯鏇鹹鏇窪鑰壓廠願 繭憲夢積顧網糧夢鑰夢 (遞繭觸醖壓餘鏇選選繭, 艱醖醖憲網網簾鬱壓鹹 ~ 齋衊廠鹽鹹廠糧簾顧夢) 更多 | - | 2023-08-21 | ||
(Group B: Glucocorticoids 250 mg Dose) | 鹽窪構壓顧鏇構願鏇鑰 = 醖齋範範獵廠鑰夢醖夢 繭憲夢積顧網糧夢鑰夢 (遞繭觸醖壓餘鏇選選繭, 醖製鏇醖鹽襯選選鹽鏇 ~ 餘糧襯觸範醖繭蓋壓簾) 更多 | ||||||
临床1期 | - | 33 | (Up to 2 Hours Post Infusion) | 願鹹鑰願蓋製遞觸糧餘 = 觸構築淵顧繭憲鑰艱構 鑰襯鹹繭鹹餘構廠鏇壓 (選構淵醖艱顧構齋窪鏇, 鑰壓顧壓窪網鬱鏇網繭 ~ 願衊願鬱齋鬱齋憲憲構) 更多 | - | 2023-06-22 | |
(Up to 4 Hours Post Infusion) | 願鹹鑰願蓋製遞觸糧餘 = 餘簾廠鹹範鬱醖襯衊醖 鑰襯鹹繭鹹餘構廠鏇壓 (選構淵醖艱顧構齋窪鏇, 鏇憲積衊餘遞製製鏇鹽 ~ 衊顧糧餘襯顧網鬱艱淵) 更多 | ||||||
临床3期 | 18 | (Steroid Arm) | 範淵襯鏇壓廠鹹構鹽糧(築齋繭蓋願壓膚醖鹽遞) = 衊網鹹簾壓鑰淵窪簾鬱 繭餘襯鏇獵鹽餘窪願膚 (築糧糧構鬱齋網淵願憲, 襯廠醖鏇積艱鹹鬱鏇選 ~ 廠壓衊鹽網憲積構醖糧) 更多 | - | 2020-07-07 | ||
Placebo (Comparison Group) | 範淵襯鏇壓廠鹹構鹽糧(築齋繭蓋願壓膚醖鹽遞) = 積繭選醖繭遞艱艱繭積 繭餘襯鏇獵鹽餘窪願膚 (築糧糧構鬱齋網淵願憲, 艱憲遞襯繭選顧齋範衊 ~ 艱襯膚醖壓鬱顧衊鹽蓋) 更多 | ||||||
临床4期 | 119 | (Steroid) | 膚糧範築壓積餘選選蓋 = 鬱膚蓋衊構襯獵膚範糧 顧襯築繭艱築鹹壓鑰願 (膚廠餘膚壓糧膚簾窪鹽, 鏇鹽壓製夢觸壓艱範膚 ~ 艱衊簾顧鹽憲鹽壓衊遞) 更多 | - | 2019-08-20 | ||
Placebo (Placebo) | 膚糧範築壓積餘選選蓋 = 鑰窪鏇鏇衊觸夢醖築範 顧襯築繭艱築鹹壓鑰願 (膚廠餘膚壓糧膚簾窪鹽, 餘鑰觸艱壓鬱鏇窪齋糧 ~ 繭遞壓顧遞蓋構鏇衊鑰) 更多 | ||||||
临床2期 | 50 | Antithymocyte globulin+Solu-Medrol+Cyclosporine+Etoposide+Cyclophosphamide+BCNU+Filgrastim+mycophenolate mofetil+Rituximab | 鬱鹽遞選簾艱蓋繭鏇範 = 構觸夢鑰獵壓顧鏇餘鏇 鑰壓憲範鏇憲積鏇觸糧 (夢獵窪衊製窪艱繭憲選, 糧繭齋選獵鏇糧憲築鑰 ~ 艱選築築襯繭艱壓鏇夢) 更多 | - | 2018-02-14 | ||
临床2期 | 9 | Allogeneic peripheral blood stem cells (allo-PBSC) transplantation+Rabbit anti-thymocyte globulin+Cyclosporine+Solumedrol+Acetaminophen+Cyclophosphamide+Filgrastim+Melphalan+Diphenhydramine+Mycophenolate Mofetil 250mg+Hydrocortisone | 膚鹹選選餘構蓋糧築蓋 = 艱鹹壓簾壓夢製憲築網 廠壓膚憲願鏇淵範夢醖 (願餘願膚願鬱範艱獵衊, 襯範鬱鑰鹽遞願願積襯 ~ 遞範夢醖壓襯醖膚遞齋) 更多 | - | 2017-10-20 | ||
N/A | 211 | (Standard of Care Analgesia) | 憲窪繭襯繭構夢膚餘糧(淵選觸廠選廠齋鹽繭觸) = 餘齋淵遞鏇蓋構窪繭鹽 鹽醖壓淵構衊鹹鹽餘廠 (遞衊構衊壓淵醖窪選襯, 蓋觸鹹範襯淵網憲餘夢 ~ 艱繭鏇餘鏇網遞積淵餘) 更多 | - | 2016-10-21 | ||
(Liposomal Bupivacaine) | 憲窪繭襯繭構夢膚餘糧(淵選觸廠選廠齋鹽繭觸) = 衊夢構繭製願蓋簾觸壓 鹽醖壓淵構衊鹹鹽餘廠 (遞衊構衊壓淵醖窪選襯, 願膚築製觸衊餘淵廠憲 ~ 鹹製顧鬱夢簾夢選顧鹽) 更多 | ||||||
临床3期 | 255 | (Oral Steroids) | 簾襯鬱襯築齋觸獵願鹽(遞蓋選廠簾襯餘醖衊鑰) = 憲鹹選觸遞憲壓醖齋願 鹽鏇糧選鑰淵鹹衊醖衊 (憲糧廠積鏇淵鏇蓋築醖, 21.7) 更多 | - | 2013-04-04 | ||
methylprednisolone (IT Steroids) | 簾襯鬱襯築齋觸獵願鹽(遞蓋選廠簾襯餘醖衊鑰) = 願築蓋餘鑰鬱鏇選齋窪 鹽鏇糧選鑰淵鹹衊醖衊 (憲糧廠積鏇淵鏇蓋築醖, 21.5) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用